Skip Navigation



Journal of the National Cancer Institute Advance Access published online on May 13, 2008
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djn168
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
100/10/694    most recent
djn168v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schmidt, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Oxford University Press 2008.

NEWS

Lapatinib Study Supports Cancer Stem Cell Hypothesis, Encourages Industry Research

Charles Schmidt

The first 150 words of the full text of this article appear below.

Last year, scientists reported for the first time that the drug lapatinib (Tykerb) can cause complete tumor regression, possibly by killing cancer stem cells. Presented at the San Antonio Breast Cancer Conference on December 17, the findings showed that among 40 women with HER2-positive breast cancer who took lapatinib for 6 weeks—followed by 6 weeks of standard chemotherapy and trastuzumab—63% experienced a "pathologically complete response," meaning that there was no evidence of any remaining tumor. Jenny Chang, M.D., an associate professor at the Baylor College of Medicine in Houston, who led the study, said that 10%–20% of the women would probably have achieved a pathologically complete response with chemotherapy alone; this figure rises to 30% with chemotherapy and trastuzumab combined. "So, these are very exciting findings," she said. "We know that women with a pathologically complete response have the least likelihood of a recurrence." Chang's study is now undergoing . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?